Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer 18F-4FMFES in Estrogen Receptor-Positive Breast Cancer Patients: An Ongoing Phase II Clinical Trial

Conclusion: This phase II study with ER+ breast cancer patients showed that 18F-4FMFES PET achieves a lower nonspecific signal and better tumor contrast than 18F-FES PET, resulting in improved diagnostic confidence and lower false-negative diagnoses.

Source: Journal of Nuclear Medicine - February 1, 2018 Category: Nuclear Medicine Authors: Paquette, M., Lavallee, E., Phoenix, S., Ouellet, R., Senta, H., van Lier, J. E., Guerin, B., Lecomte, R., Turcotte, E. E. Tags: Clinical Source Type: research